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dent hypertension associated with the use of celecoxib and non-
selective (NS) NSAIDs in a real world setting. METHODS: A
cohort study was conducted using secondary data from the GE
Centricity® Electronic Medical Record database, which contains
the medical records of 3 million patients seen by 5000 physicians
in 27 states across the US. The index date was deﬁned as the
date of the ﬁrst NS NSAID or celecoxib prescription between
January 1, 1999 and June 30, 2004. Patients were included if
they were aged 18 or older and were enrolled for at least 365
days prior to the index date. NS NSAID users were matched to
celecoxib users using propensity-based matching techniques by
a 2 : 1 ratio. Multivariate Cox proportional hazard models were
used for the analysis. RESULTS: The ﬁnal sample consisted of
51,444 patients. Among the 17,148 celecoxib users, 222 (1.3%)
had a new diagnosis of hypertension, while 446 out of the
34,296 NS NSAID users (1.3%) had a new diagnosis of hyper-
tension. The crude incidence rate for hypertension was slightly
higher for celecoxib users: 52.5 vs. 51.8 per 1000 patient per
year for celecoxib and NS NSAID users, respectively. Relative to
NS NSAID users, patients on celecoxib had a similar rate of post
exposure hypertension incidence in multivariate analyses (HR =
1.006; 95% CI: 0.856–1.181). CONCLUSION: Results from a
population-based cohort analysis of electronic medical records
suggest similar rates of incident hypertension between celecoxib
and NS NSAID users.
CARDIOVASCULAR STUDIES—Cost Studies
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DETENTION PROGRAMS IN HYPERTENSIVE MEXICAN
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OBJECTIVES: To assess the economic impact in the Mexican
Health System of a hypertensive population preventive program
(HPPP) in order to shift cardiovascular risk on the long-term.
METHODS: Costs and health beneﬁts were forecasted for the
period 2005–2025 after the implementation of a control and
detention program in hypertensive population in Mexico. Inci-
dence and prevalence data was obtained from a Mexican
National Survey (Encuesta Nacional de Salud 2000) for popula-
tion between 20–59 yrs. Preventive actions included in the
program were: opportune detention of hypertension with two
measures of arterial hypertension per year to all adult popula-
tion attended in the Mexican Health System. Secondary preven-
tion actions consisted in changes in life styles and intensive
pharmacologic treatment in patients with uncontrolled hyper-
tension. Health care costs data was obtained from the Social
Security Mexican Institute (IMSS) databases and the HPPP effec-
tiveness was taken from published literature for worldwide
similar preventive programs. Framingham tables were used to
constructed disease progression simulations and effectiveness
measures used in the assessment were the number of new cases
of patients controlled and cardiovascular events avoided. The
analysis was conducted from the health care payer’s perspective
(only direct medical costs were used). RESULTS: Through 20-
years analysis period, the total number of hypertensive cases
remained unchanged. Nevertheless, the number of new hyper-
tensive cases controlled increased in 74.8% which represented a
reduction of 6.6 millions cases uncontrolled. On the same time
horizon, the HPPP showed a decrease of 16.9% in the total
number of cardiovascular events which represented approxi-
mately 1.7 millions less complications in the Mexican Health
System. The latter could represent in the future net savings in
US$1652 millions compared to the actual scenario. CONCLU-
SION: Preventive actions included in control and detention
hypertensive programs resulted to be cost-effectiveness policies,
and showed to be cost saving strategies in the long-term.
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COMPARING THE COST OF MICROSURGERY AND
RADIOSURGERY FOR THE MANAGEMENT OF VESTIBULAR
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OBJECTIVES: To investigate differences in follow-up costs of
patients undergoing microsurgical resection, which requires hos-
pitalization, compared to steriotactic radiosurgery, an outpatient
procedure, for the treatment of vestibular schwannoma.
METHODS: Post-surgical medical utilization records and cost
data were retrospectively gathered for 82 patients undergoing
microsurgery or radiosurgery. Follow-up costs were obtained
using administrative datasets and were discounted. Thirty-one
patients did not have any follow-up care at our facilities. For
patients seeking follow-up care elsewhere utilization records
(prospectively gathered) were matched to our administrative
costs using median values. To adjust for varying lengths of
follow-up, the cohort was reduced to those having a minimum
length of follow-up of 28 months. Results were veriﬁed with 36
months of follow up. RESULTS: In the initial cohort, age and
patient location were signiﬁcantly associated with surgery type.
Radiosurgery patients tended to be older. Mean costs per month
using a six month moving average for microsurgery patients ini-
tially were high and leveled off to below $200 per month. Con-
versely mean follow-up costs for radiosurgery patients started
low and ﬂuctuated through high and low cycles, reaching as high
as $200 per month. CONCLUSIONS: Many of the radiosurgery
patients did not have follow-up at our facility so we estimated
them from surgery-related follow-up utilization. In addition,
radiosurgery is a relatively new procedure and clinicians are not
yet in agreement on a reasonable length of follow-up. Including
other health care costs for these patients and accounting for
longer follow-up length would likely increase the mean follow-
up costs of radiosurgery further relative to microsurgery. This
may make the total cost (the sum of initial and follow-up costs)
of the two procedures more comparable.
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OBJECTIVES: A decision analytic model was created to
compare the potential economic beneﬁts (cost-offsets and cost-
effectiveness) of treatment planning for peripheral arterial
disease (PAD) with either digital subtraction angiography (DSA)
and magnetic resonance angiography (MRA) technology in a
diabetic population. METHODS: The model considered degree
of stenosis, outcomes associated with a treatment plan, risk of
complications from DSA and MRA, and associated costs of
treatment. Sensitivity and speciﬁcity for DSA, considered the
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“gold standard”, were set at 100%, while ranges for sensitivity
and speciﬁcity for MRA were drawn from literature and used
for sensitivity analysis. Analyses performed for a hypothetical
population of 91,665 (US diabetics with PAD who are eligible
for treatment in 2000) included: one-year total health care costs,
total Quality Adjusted Life Year Gained (QALYG; the increase
in quality of life after treatment), cost per QALYG, incremental
cost per QALY, and cost of accurate and inaccurate planning
with medical management, PTA, bypass, and amputation.
RESULTS: In the base-case scenario, with MRA sensitivity and
speciﬁcity at 98% and 83% respectively, the one-year per patient
total health care costs in the diabetic PAD population was
$20,176 for patients receiving an MRA versus $21,996 for those
receiving a DSA for treatment planning. The total QALYG were
higher in the MRA cohort than in the DSA cohort, 0.11 versus
0.07 respectively. Therefore, the total cost per QALYG was
$106,948 higher for patients who received a DSA ($190,697 vs.
$297,645). MRA dominates the DSA in incremental cost/QALY
with savings of $57,060, due to a lower risk of complication and
the resultant greater increase in QALYG and lower cost of treat-
ment. CONCLUSION: This model demonstrates that MRA as
a treatment-planning tool, with lower risk of complication, could
substantially reduce the cost and cost per quality-adjusted life
years for peripheral arterial disease in diabetic patients.
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OBJECTIVES: Nearly 600,000 patients are diagnosed with Deep
Vein Thrombosis (DVT) in US every year. One in every 100
patient dies due to pulmonary embolism developed as a later
complication. DVT during abdominal surgery is a frequent
problem & therefore prophylaxis is a compulsion. The objective
of this study was to identify the least costly prophylactic treat-
ment taking into account DVT complications from the health
care payer perspective. METHODS: Cost comparison was done
using a decision tree. The probabilities and costs for postopera-
tive DVT was obtained from clinical trial studies and other pub-
lished sources. Prophylaxis during surgery was considered to 
be for 9 days whereas treatment for postoperative DVT was
assumed to be for 5 days. Total cost included drug acquisition
cost, hospitalization costs for DVT. Expected value was com-
puted at each chance nodes. RESULTS: Fondaparinux sodium
has the least probability (0.042) for postoperative DVT compli-
cations whereas Enoxaparin sodium & unfractionated heparin
(UFH) have higher probabilities of 0.048 & 0.11 respectively.
The drug acquisition cost for prophylaxis was highest with fon-
daparinux sodium (2.5 mg) at $36.69, enoxaparin sodium (40
mg) at $24.74 & UFH (5000 IU) at $3.06 per single dose. Low
molecular weight heparins were given once daily while UFH was
given twice daily. Expected value was found to be $1129.720,
$1133.590 & $2256.730 for fondaparinux sodium, enoxaparin
sodium & UFH respectively. Sensitivity Analysis showed that the
model is somewhat inﬂuenced by adverse events & costs. CON-
CLUSION: Fondaparinux sodium has been found to have 
the least costly prophylactic treatment. Although the acquisition
cost is the highest, it is offset by the low probability of deve-
loping DVT complications and later hospitalization costs. UFH
even though having the lowest acquisition cost, has high rate 
of DVT complications & higher hospitalization cost due to 
frequent administration procedures & continuous monitoring
requirement.
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OBJECTIVES: To compare the costs resulting from a treatment
with ivabradine, a new medication for stable angina pectoris
patients, with standard care for those patients who cannot be
appropriately treated with standard medication in The Nether-
lands in 2006. METHODS: A decision analytic model was used
to estimate the cost-effectiveness of ivabradine in patients with
stable angina pectoris, who cannot be appropriately treated with
standard medication and are therefore currently candidates for
revacularisation (ESC guidelines 2006 on the management of
stable angina pectoris). Therefore ivabradine is compared with
standard care consisting of revascularization (CABG or PTCA).
The study was performed within the society perspective, which
included costs of medication and revascularisation procedures.
The data sources included published literature, the ivabradine
clinical trials, the Euro Heart Survey for stable angina, which
provided data from daily practice, and ofﬁcial price/tariff 
lists and national population statistics. RESULTS: Treatment
with ivabradine results in 77% reduction in revascularisation
and leads to a cost saving of €7028 per patient compared with
revacularisation during the ﬁrst year of treatment. Sensitivity
analyses showed that extrapolation beyond one year leads to
further cost savings. Another sensitivity analysis on the proba-
bility of revascularisation showed that cost savings vary from
€2882 to €9102. CONCLUSION: This model showed that the
use of ivabradine compares favourably with revascularisation in
treatment of stable angina pectoris in The Netherlands from a
budgetary and health economic perspective: the total costs are
substantially lower, whereas the effectiveness is at least similar.
Consequently ivabradine can be considered a cost-effective
treatment being dominant over standard care.
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OBJECTIVES: In Mexico in 2005, there are more than 250,000
patients in secondary prevention. One of the most serious and
frequent consequences of survivors of acute myocardial infarc-
tion (AMI) is heart failure, which is associated with a 55%
greater risk of dying and 2.15-times- greater risk of death or
recurrent AMI at 30 days. The purpose of this study was to 
evaluate the cost—effectiveness of eplerenone compared with
placebo from the Mexican health care payer’s perspective.
METHODS: We used a three-year analysis model to estimate
costs and effectiveness. Effectiveness measures were the num-
ber of life-year gained (LYG) and quality-adjusted life-years
(QALYs). Effectiveness data was obtained from the Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and
Survival Study (EPHESUS). Survival beyond the trial period (16
months) was estimated from data from the Framingham Heart
Study. The estimation of resource use was performed employing
local expert opinion surveys and they included hospitalization,
emergency room visits, outpatient services and medication. Costs
and life expectancy differences were discounted 5% annually.
Threshold sensitivity analysis was performed and acceptability
